BioTuesdays Feature Articles | Life Sciences News

Feature

MiMedx’s proprietary tissue technology utilizing amniotic tissue as a platform for regenerative medicine

MiMedx Group (NASDAQ:MDXG) is forging ahead with its corporate turnaround as an industry leader in advanced wound care. “As a pioneer in amniotic tissue biologics, we have both a core business, focused on addressing the...

May 11, 2021

Feature

TransMedics redefining what’s possible in organ transplantation

TransMedics Group (NASDAQ:TMDX) is transforming the standard of care in solid organ transplants in order to increase the number of organ transplants and improve clinical outcomes.

May 4, 2021

Feature

Stuart Long outlines InfoBionic remote cardiac arrhythmia monitoring benefits

As CEO of InfoBionic, a closely held digital health company with an initial focus on cardiac arrhythmia detection and monitoring, Stuart Long knows his way around achieving commercial growth in the medical device market...

April 27, 2021

Feature

ViaCyte developing stem cell-derived islet replacement for diabetes

Closely held ViaCyte, a company with two decades of experience, is utilizing pluripotent stem cell technology and novel delivery approaches to address multiple disease areas, with an initial focus and lead products...

April 20, 2021

Feature

Cyclacel translating cancer biology into potential medicines

Cyclacel (NASDAQ:CYCC) is developing several innovative therapies that target various phases of cell cycle control for the treatment of solid tumor and blood-borne cancers, such as leukemia.

April 13, 2021

Feature

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

As CEO of closely-held Nurx, the leading female-focused telehealth platform offering patients transparent pricing and judgment-free care, Varsha Rao brings decades of experience balancing mission-driven companies with a...

March 30, 2021

Feature

KA Imaging Reveal device a game changer in reinventing X-ray with dual energy

X-ray manufacturer, KA Imaging, is reinventing dual energy X-rays with its Reveal 35C device, which can produce three images from a single exposure, overcoming clinical and technical issues that exist with traditional X...

March 23, 2021

Feature

Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy

Petros Pharmaceuticals (NASDAQ:PTPI) has set up a steering committee with the aim of applying to the FDA to make its prescription erectile dysfunction (ED) therapy, Stendra, available as an over-the-counter product in a...

March 16, 2021

Feature

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

Kezar Life Sciences (NASDAQ:KZR) is advancing two drug development programs that have the potential to address a number of indications by harnessing different “master regulators” of cellular function: protein...

March 9, 2021

Feature

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Shanghai-based 111, Inc. (NASDAQ:YI) is helping pioneer the S2B2C model in China as it builds an innovative healthcare platform in the country.

March 2, 2021

Feature

Keith Sullivan discusses turnaround plan for Neuronetics

As the recently installed president and CEO of Neuronetics (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing and marketing products that improve the quality of life for patients...

February 23, 2021

Feature

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

Achieve Life Sciences (NASDAQ:ACHV) began a pivotal trial in the fourth quarter of 2020 to evaluate cytisinicline, which is derived from the seeds of the laburnum tree, as a potential new treatment for smoking cessation...

February 16, 2021

Feature

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

VistaGen Therapeutics (NASDAQ:VTGN) plans to begin a Phase 3 clinical trial in the second quarter with PH94B, a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in...

February 9, 2021

Feature

ARSTAT developing portfolio of transformational products for women’s health

Closely held ARSTAT Pharmaceuticals is advancing two patented Phase 3-ready assets: Nuvocept, the first and only oral contraceptive designed for overweight and obese women, and another contraceptive brand, Duacept, as a...

February 2, 2021

Feature

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) expects to report important milestones in its cell therapy clinical programs in dry AMD, cervical spinal cord injury and oncology in 2021, as well as improve its...

January 26, 2021

Feature

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...

January 19, 2021

Feature

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Tarsus Pharmaceuticals (NASDAQ:TARS) launched the Phase 2b/3 Saturn-1 clinical trial in September 2020 with its lead asset, TP-03, as the potential first therapeutic for Demodex blepharitis, where eyelids become red...

January 12, 2021

Feature

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Closely held Ripple Therapeutics inked a transformative strategic investment and licensing deal for its lead product candidate, IBE-814 IVT, an intravitreal implant being developed for the treatment of diabetic macular...

December 15, 2020

Feature

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Plus Therapeutics (NASDAQ:PSTV) is developing its lead asset, rhenium nanoliposome (RNL), a targeted and potentially more potent radionucleotide therapy, for the treatment of recurrent glioblastoma and several other...

December 8, 2020

Feature

Genelux advancing oncolytic vaccinia virus into pivotal ovarian cancer trial in 2021

Closely-held Genelux expects to arrange an end-of-Phase 2 meeting with the FDA in the first quarter of 2021 and then launch a Phase 3 trial in mid-year with its Olvi-Vec vaccinia virus in combination with chemotherapy...

December 1, 2020

Feature

Izotropic Breast CT Imaging System targeting earlier cancer detection

Izotropic (CSE:IZO; OTC:IZOZF; FSE:1R3) is developing a dedicated breast imaging system aimed at the better detection – and potentially earlier diagnosis and treatment – of breast cancer.

November 24, 2020

Feature

Kintara Therapeutics readies two late-stage cancer drug candidates

Kintara Therapeutics (NASDAQ:KTRA), fresh off a merger and $25-million private placement, is moving into a global registration trial in newly-diagnosed and recurrent glioblastoma multiforme (GBM), a deadly brain cancer...

November 17, 2020

Subscribe